AzurRx BioPharma to Present at Rocky Mountain Microcap Conference (May 26)
19 mai 2021 07h30 HE
|
AzurRx BioPharma, Inc.
DELRAY BEACH, Fla., May 19, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development of...
AzurRx BioPharma Announces Positive Interim Data in Phase 2 Clinical Trial of MS1819 in Combination with PERT in the Treatment of Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency
13 mai 2021 07h00 HE
|
AzurRx BioPharma, Inc.
Data from first 18 patients indicate MS1819 and PERT combination led to clinically meaningful improvements in primary efficacy endpoint Full top-line data expected in Q2 2021 DELRAY BEACH, Fla., May...
AzurRx BioPharma to Participate in the 33rd Annual Roth Conference
08 mars 2021 07h00 HE
|
AzurRx BioPharma, Inc.
DELRAY BEACH, Fla., March 08, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic,...
AzurRx BioPharma to Participate in “Fireside Chat” at the H.C. Wainwright Global Life Sciences Conference
02 mars 2021 07h00 HE
|
AzurRx BioPharma, Inc.
DELRAY BEACH, Fla., March 02, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic,...
AzurRx BioPharma Appoints President and CEO James Sapirstein as New Chairman of the Board of Directors
24 févr. 2021 07h00 HE
|
AzurRx BioPharma, Inc.
DELRAY BEACH, Fla., Feb. 24, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development...
AzurRx BioPharma Adds Two New Clinical Trial Sites in Europe for Phase 2b OPTION 2 Extension Study of MS1819 Immediate-Release Capsules in Cystic Fibrosis Patients
26 janv. 2021 07h00 HE
|
AzurRx BioPharma, Inc.
DELRAY BEACH, Fla., Jan. 26, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic,...
AzurRx BioPharma Announces First Two Patients Dosed in Phase 2b OPTION 2 Extension Study of MS1819 in Cystic Fibrosis Patients
21 janv. 2021 08h00 HE
|
AzurRx BioPharma, Inc.
DELRAY BEACH, Fla., Jan. 21, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic,...
AzurRx BioPharma to Participate in 10th Annual LifeSci Partners Corporate Access Event
05 janv. 2021 08h00 HE
|
AzurRx BioPharma, Inc.
DELRAY BEACH, Fla., Jan. 05, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a company specializing in the development of targeted,...
AzurRx BioPharma Announces First Patients Dosed in Turkey for Phase 2 Combination Therapy Trial of MS1819 in Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency
30 nov. 2020 08h00 HE
|
AzurRx BioPharma, Inc.
Patient screening and dosing ongoing in Turkey and HungaryTopline data expected in Q2 2021 for the Combination Trial DELRAY BEACH, Fla., Nov. 30, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc....
AzurRx BioPharma Requests Protocol Amendment to Phase 2b OPTION 2 Study of MS1819 in Cystic Fibrosis Patients
17 nov. 2020 08h00 HE
|
AzurRx BioPharma, Inc.
Potential to add additional study arm utilizing immediate release capsules Trial objectives, endpoints and statistical analysis to remain the same DELRAY BEACH, Fla., Nov. 17, 2020 (GLOBE...